BIO-TECHNE Corp Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax
BIO-TECHNE Corp (TECH) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax of -$1.79 million for the 9-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax · last filed 2019-05-07
- BIO-TECHNE Corp other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for the quarter ending 2019-03-31 was -$576.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 9 month |
|---|---|---|---|
| 2019-03-31 | -$576.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-07 | -$1.79M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | -$1.22M 10-Q · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |